- Academic Editor
-
-
-
†These authors contributed equally.
Background: The aim of this study was to investigate the impact of body
mass index (BMI) and body weight on the concentrations of ticagrelor and the
ticagrelor metabolite, AR-C124910XX, as well as the platelet aggregation rate
(PAR) in a Chinese Han population with unstable angina (UA). Specifically, it
focused on these parameters following the administration of dual antiplatelet
therapy (DAPT) comprising aspirin and ticagrelor. Methods: A total of
105 patients with UA were included in the study. Measurement of the platelet
aggregation rate induced by adenosine diphosphate (PAR-ADP) was performed before,
as well as 3 and 30 days after DAPT treatment. The plasma concentrations of
ticagrelor and AR-C124910XX were detected at 3 and 30 days after DAPT treatment.
We conducted correlation analyses to assess the effects of BMI and body weight on
the concentrations of ticagrelor and AR-C124910XX, on PAR-ADP, and on the
inhibition of platelet aggregation induced by adenosine diphosphate (IPA-ADP) at
both 3 and 30 days after DAPT treatment. Results: The BMI and body
weight were positively correlated with baseline PAR-ADP (r = 0.205,
p = 0.007; r = 0.122, p = 0.022). The PAR-ADP at 3 and
30 days after DAPT treatment were significantly lower than at baseline (61.56%